Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter B

GENERIC NAME	TRADE NAME	CONDITION	STUDY CODE	STUDY NAME	ACCESS TO STUDY / PROTOCOL	ACCESS TO RESULTS
BACILLUS CLAUSII	Enterogermina	Diarrhea	LPS16140	EPIC	EudraCT Number: 2020-000970-10	Tabulated Results
BACILLUS CLAUSII	Enterogermina	Diarrhea	ENTER_L_01125	PADRE	NCT00447161	Summary
BACILLUS CLAUSII	Enterogermina	Diarrhea	ENTER_L_01486	ENIGMA	NCT00457353	Summary
BACILLUS CLAUSII	Enterogermina	Gastrointestinal Diseases	LPS15198	BASTA	EudraCT: 2018-001355-12	Tabulated Results
BACILLUS CLAUSII	Enterogermina	Gastrointestinal Diseases	PM_L_0161	EFESO	EudraCT: 2005-004934-42	Summary Results
BACILLUS CLAUSII	Enterogermina	Infection	PM_L_0199	DIAMANTE	NCT00424905	Summary
BACILLUS CLAUSII	Enterogermina	Diarrhea	ENTERR06929	cadiLAc	EudraCT: 2016-003444-37	Tabulated Results
BACILLUS CLAUSII	Enterogermina	Diarrhea	LPS14914	KIDDIE	2016-005165-31	Tabulated Results
BACILLUS CLAUSII	Enterogermina	Irritable Bowel Syndrome	ENTERL08784	BaclauSII	2018-004519-31	Tabulated Results
BACTERIAL LYSATES	Pulmonarom	Medical Prevention Therapy	BACLY_L_03329	NA	NCT00599417	Summary
BAMADUTIDE	Not marketed	Diabetes Mellitus, Type 2	DRI13940	NA	NCT02973321	Tabulated Results
BAMADUTIDE	Not marketed	Diabetes Mellitus, Type 2	PDY15012	NA	NCT03376802	Summary
BAMADUTIDE	Not marketed	Diabetes Mellitus, Type 2	PDY15264	NA	NCT03350191	Summary
BAMADUTIDE	Not marketed	Diabetes Mellitus, Type 2	TDR13700	NA	NCT02411825	Publication's Reference
BAMADUTIDE	Not marketed	Diabetes Mellitus, Type 2	TDR15516	NA	NCT03414736	Summary
BELUMOSUDIL	Rezurock	Bioavailability	KD025-106	NA	NCT02557139	Tabulated Results
BELUMOSUDIL	Rezurock	Drug-drug Interaction Autoimmune Diseases Fibrotic Disease	KD025-107	NA	NCT03530995	Tabulated Results
BELUMOSUDIL	Rezurock	Autoimmune Diseases Fibrosis	KD025-108	NA	NCT03907540	Tabulated Results
BELUMOSUDIL	Rezurock	Chronic Graft Versus Host Disease (cGVHD)	KD025-208 / ACT17631	NA	NCT02841995	Publication reference
BELUMOSUDIL	Rezurock	Chronic Graft Versus Host Disease (cGVHD)	KD025-213 / DRI17633	NA	NCT03640481	Publication reference
BELUMOSUDIL	Not Marketed	Psoriasis Vulgaris	KD025-205/ACT17656	NA	NCT02106195	Tabulated Results
BELUMOSUDIL	Not Marketed	Psoriasis Vulgaris	KD025-206/DFI17657	NA	NCT02317627	Tabulated Results
BELUMOSUDIL	Not Marketed	Chronic Plaque Psoriasis	KD025-211/EFC17658	NA	NCT02852967	Tabulated Results
BELUMOSUDIL	Not Marketed	Idiopathic Pulmonary Fibrosis	KD025-207 / EFC17630	NA	NCT02688647	Tabulated Results
BELUMOSUDIL	Rezurock	Bioavailability	KD025-111	NA	NCT04735822	Summary
BIVV001	Not marketed	Hemophilia A	TDU16220	NA	NCT03205163	Tabulated Results

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted